PINPOINT Feasibility Study
Primary Purpose
Prostate Cancer, Image Guided Radiotherapy
Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Imaging
Sponsored by
About this trial
This is an interventional other trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- Patient has undergone radical prostatectomy
- Histologically confirmed prostate cancer
- Patient due to receive post-operative prostate bed +/- pelvic lymph node radiotherapy
- WHO performance status 0-1
- Age ≥ 18 years
- Written informed consent
Exclusion Criteria:
- Recruitment into POPS trial
- Contraindications to MRI such as having a pacemaker or non-MRI compatible implanted device
Sites / Locations
- Sophie AlexanderRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Standard radiotherapy with research image acquisition
Arm Description
Radiotherapy delivered as per standard of care Additional trans-perineal ultrasound (TPUS) imaging at three timepoints (1 x pre-treatment and 2 x treatment). Additional magnetic resonance imaging (MRI) pre-treatment.
Outcomes
Primary Outcome Measures
Reliability of anatomical structure visualisation
Reliability of anatomical structure visualisation determined by mean dice similarity coefficient (DSC) and mean surface-to-surface distance (MSSD) for delineated structures (urethra, bladder neck, VUA, retrovesicle space, penile bulb, pubic symphysis and rectum) on MRI, CT, TPUS and CBCT across observers. If DSC is ≥ 0.75 the structure is deemed to be reliably visible.
Frequency of anatomical structure visualisation
Frequency of anatomical structure visualisation by average user rating of urethra, bladder neck, VUA, retrovesicle space, penile bulb, public symphysis and anterior rectal wall visualisation on MRI, CT, TPUS, CBCT and fused multimodality imaging (CT, MRI, TPUS).
Secondary Outcome Measures
Anatomical structure motion
On TPUS, the distance (mm) between anterior rectal wall and posterior pubic symphysis measured every 30 seconds over 10 minutes and the distance (mm) between VUA and superior aspect of penile bulb measured every 30 seconds over 10 minutes.
Full Information
NCT ID
NCT05481372
First Posted
July 28, 2022
Last Updated
July 28, 2022
Sponsor
Royal Marsden NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT05481372
Brief Title
PINPOINT Feasibility Study
Official Title
Pioneering Imaging Techniques for Optimising Dose Delivery in Post-Operative Prostate Radiotherapy. A Feasibility Study.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royal Marsden NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This feasibility study is investigating the application of magnetic resonance imaging (MRI) and transperineal ultrasound (TPUS) to visualise potential sites of relapse and surrounding normal tissue in patient having post-operative prostate cancer radiotherapy. Structure visualisation on MRI and TPUS will be compared to current standard computer tomography (CT) and cone-beam computer tomography (CBCT) imaging.
Detailed Description
Approximately 47,000 men are diagnosed with prostate cancer yearly in the UK, 15% of which receive surgery (radical prostatectomy) as primary treatment. Of these men one third develop recurrence after prostatectomy and are offered post-operative radiotherapy.
Radiotherapy is targeted at the area where the prostate used to be, this includes potential relapse sites (PRS); vesicourethral anastomosis, bladder neck and retrovesicle space. When planning post-operative radiotherapy, the lack of a visible target means surrounding normal tissue is used to guide clinical target volume (CTV) delineation. The CTV is the area of tissue to be treated to the full radiotherapy prescription and includes PRS. Typically, the CTV is defined on a radiotherapy planning computer tomography (CT) scan.
The CTV lies adjacent to the bladder and rectum and is highly susceptible to positional changes influenced by organ filling. To identify and correct for CTV displacement during daily radiotherapy a cone-beam CT (CBCT) is acquired, this is an image similar to a CT scan but taken immediately prior to treatment delivery.
CT visualisation of PRS has been reported as inadequate, increasing the risk of missing or miss-identifying CTV structures during radiotherapy planning and delivery. To compensate for restricted visualisation on CT and CBCT an additional 1cm circumference around the CTV is treated to the prescription dose, this volume is referred to as the planning target volume (PTV). This margin reduces the risk of missing the target however its inclusion of normal tissue increases the risk of patient toxicity.
We propose that visualisation of PRS and surrounding normal tissue structures is enhanced on magnetic resonance imaging (MRI) compared to CT and on transperineal ultrasound (TPUS) compared to CBCT. This project investigates the reality of this statement by quantifying the confidence and reliability with which anatomical structures can be identified and delineated on all four image types.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer, Image Guided Radiotherapy
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single centre feasibility study
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard radiotherapy with research image acquisition
Arm Type
Experimental
Arm Description
Radiotherapy delivered as per standard of care Additional trans-perineal ultrasound (TPUS) imaging at three timepoints (1 x pre-treatment and 2 x treatment). Additional magnetic resonance imaging (MRI) pre-treatment.
Intervention Type
Other
Intervention Name(s)
Imaging
Intervention Description
Trans-perineal ultrasound and Magnetic resonance image acquisition
Primary Outcome Measure Information:
Title
Reliability of anatomical structure visualisation
Description
Reliability of anatomical structure visualisation determined by mean dice similarity coefficient (DSC) and mean surface-to-surface distance (MSSD) for delineated structures (urethra, bladder neck, VUA, retrovesicle space, penile bulb, pubic symphysis and rectum) on MRI, CT, TPUS and CBCT across observers. If DSC is ≥ 0.75 the structure is deemed to be reliably visible.
Time Frame
14 months
Title
Frequency of anatomical structure visualisation
Description
Frequency of anatomical structure visualisation by average user rating of urethra, bladder neck, VUA, retrovesicle space, penile bulb, public symphysis and anterior rectal wall visualisation on MRI, CT, TPUS, CBCT and fused multimodality imaging (CT, MRI, TPUS).
Time Frame
14 months
Secondary Outcome Measure Information:
Title
Anatomical structure motion
Description
On TPUS, the distance (mm) between anterior rectal wall and posterior pubic symphysis measured every 30 seconds over 10 minutes and the distance (mm) between VUA and superior aspect of penile bulb measured every 30 seconds over 10 minutes.
Time Frame
14 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient has undergone radical prostatectomy
Histologically confirmed prostate cancer
Patient due to receive post-operative prostate bed +/- pelvic lymph node radiotherapy
WHO performance status 0-1
Age ≥ 18 years
Written informed consent
Exclusion Criteria:
Recruitment into POPS trial
Contraindications to MRI such as having a pacemaker or non-MRI compatible implanted device
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophie Alexander
Phone
020 8915 6053
Email
sophie.alexander@rmh.nhs.uk
Facility Information:
Facility Name
Sophie Alexander
City
Sutton
State/Province
Gastrointestinal (lower)
ZIP/Postal Code
kt5 8hx
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie Alexander
Phone
020 8915 6053
Email
sophie.alexander@rmh.nhs.uk
First Name & Middle Initial & Last Name & Degree
Julia Murray
Email
julia.murray@icr.ac.uk
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
PINPOINT Feasibility Study
We'll reach out to this number within 24 hrs